Discontinuation Approach and Follow-Up of Low-Concentration Atropine for Myopia Progression: Eight-Year Results of the LAMP Randomized Clinical Trial - PubMed
5 hours ago
- #pediatric ophthalmology
- #myopia control
- #atropine therapy
- The LAMP randomized clinical trial studied discontinuation approaches for low-concentration atropine in myopia progression over eight years, focusing on a taper versus stop method.
- Children aged 4 to 12 years who completed year 5 of the LAMP study were randomized into taper and stop groups at a 1:1 ratio for the discontinuation phase.
- During year 6 (prediscontinuation), the taper group received 0.05% atropine for 6 months followed by 0.025% for another 6 months, while the stop group used 0.05% for the full year before stopping treatment in years 7 and 8.
- Over three years, the taper group showed slower myopia progression and axial length elongation compared to the stop group, with significant differences in spherical equivalent and axial length measurements.
- A higher proportion of participants in the taper group achieved a good response to discontinuation, defined as minimal spherical equivalent progression, compared to the stop group.
- Younger age and more severe myopia at prediscontinuation were associated with faster progression, with greater benefits observed from the taper approach in these subgroups.
- The study concluded that tapering atropine resulted in less myopia progression than abrupt stopping, especially in younger, more myopic children, though the clinical relevance of the observed difference requires further investigation.